SECURITIES AND FUTURES ACT (CAP. 289) SECURITIES AND FUTURES (DISCLOSURE OF INTERESTS) REGULATIONS 2012

NOTIFICATION FORM FOR SUBSTANTIAL SHAREHOLDER(S)/UNITHOLDER(S) IN RESPECT OF INTERESTS IN

3 (Electronic Format)

FORM

Explanatory Notes

- 1. Please read the explanatory notes carefully before completing the notification form.
- This form is for a Substantial Shareholder(s)/Unitholder(s) to give notice under section 135, 136, 137, 137J (as applicable to sections 135, 136 and 137) or 137U (as applicable to sections 135, 136 and 137) of the Securities and Futures Act (the "SFA").
- 3. This electronic Form 3 and a separate Form C, containing the particulars and contact details of the Substantial Shareholder(s)/Unitholder(s), must be completed by the Substantial Shareholder(s)/Unitholder(s) or a person duly authorised by the Substantial Shareholder(s)/Unitholder(s) to do so. The person so authorised should maintain records of information furnished to him by the Substantial Shareholder(s)/Unitholder(s).
- 4. This form and Form C, are to be completed electronically and sent to the Listed Issuer via an electronic medium such as an e-mail attachment. The Listed Issuer will attach both forms to the prescribed SGXNet announcement template for dissemination as required under section 137G(1), 137R(1) or 137ZC(1) of the SFA, as the case may be. While Form C will be attached to the announcement template, it will not be disseminated to the public and is made available only to the Monetary Authority of Singapore (the "Authority").
- 5. Where a transaction results in similar notifiable obligations on the part of more than one Substantial Shareholder/Unitholder, all of these Substantial Shareholders/Unitholders may give notice using the same notification form.
- 6. A single form may be used by a Substantial Shareholder/Unitholder for more than one transaction resulting in notifiable obligations which occur within the same notifiable period (i.e. within two business days of becoming aware of the earliest transaction). There must be no netting-off of two or more notifiable transactions even if they occur within the same day.
- 7. All applicable parts of the notification form must be completed. If there is insufficient space for your answers, please include attachment(s) by clicking the paper clip icon on the bottom left-hand corner or in item 11 of Part II or item 10 of Part III. The total file size for all attachment(s) should not exceed 1MB.
- 8. Except for item 5 of Part II and item 1 of Part IV, please select only one option from the relevant check boxes.
- 9. Please note that submission of any false or misleading information is an offence under Part VII of the SFA.
- 10. In this form, the term "Listed Issuer" refers to -
 - (a) a company incorporated in Singapore any or all of the shares in which are listed for quotation on the official list of a securities exchange;
 - (b) a corporation (not being a company incorporated in Singapore, or a collective investment scheme constituted as a corporation) any or all of the shares in which are listed for quotation on the official list of a securities exchange, such listing being a primary listing;

- (c) a registered business trust (as defined in the Business Trusts Act (Cap. 31A)) any or all of the units in which are listed for quotation on the official list of a securities exchange;
- (d) a recognised business trust any or all of the units in which are listed for quotation on the official list of a securities exchange, such listing being a primary listing; or
- (e) a collective investment scheme that is a trust, that invests primarily in real estate and real estaterelated assets specified by the Authority in the Code on Collective Investment Schemes, and any or all the units in which are listed for quotation on the official list of a securities exchange, such listing being a primary listing ("Real Estate Investment Trust").
- 11. For further instructions and guidance on how to complete this notification form, please refer to section 7 of the User Guide on Electronic Notification Forms which can be accessed at the Authority's Internet website at http://www.mas.gov.sg (under "Regulations and Financial Stability", "Regulations, Guidance and Licensing", "Securities, Futures and Fund Management", "Forms", "Disclosure of Interests").

	Part I - General
1.	Name of Listed Issuer:
1.	TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED
2.	Type of Listed Issuer:
	 Registered/Recognised Business Trust Real Estate Investment Trust
3.	Is more than one Substantial Shareholder/Unitholder giving notice in this form?
	No (Please proceed to complete Part II)
	✓ Yes (Please proceed to complete Parts III & IV)
4.	Date of notification to Listed Issuer:

26-Mar-2021

Part III - Substantial Shareholder	(s)/Unitholder(S) Details

[To be used for multiple Substantial Shareholders/Unitholders to give notice]

Substantial Shareholder/Unitholder A

1.	Name of Substantial Shareholder/Unitholder:	

Jinhushen Biological Medical Science and Technology Co., Ltd

- 2. Is Substantial Shareholder/Unitholder a fund manager or a person whose interest in the securities of the Listed Issuer are held solely through fund manager(s)?
 - Yes
 - ✓ No
- 3. Notification in respect of:
 - ✓ Becoming a Substantial Shareholder/Unitholder
 - Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder
 - Ceasing to be a Substantial Shareholder/Unitholder
- 4. Date of acquisition of or change in interest:

26-Mar-2021

5. Date on which Substantial Shareholder/Unitholder became aware of the acquisition of, or the change in, interest (1) (*if different from item 4 above, please specify the date*):

26-Mar-2021

- 6. Explanation (*if the date of becoming aware is different from the date of acquisition of, or the change in, interest*):
- 7. Quantum of total voting shares/units (*including voting shares/units underlying rights/options/warrants/convertible debentures {conversion price known}*) held by Substantial Shareholder/Unitholder before and after the transaction:

Immediately before the transaction	Direct Interest	Deemed Interest	Total
No. of voting shares/units held and/or underlying the rights/options/warrants/convertible debentures:	0	0	0
As a percentage of total no. of voting shares/t	0	0	0
Immediately after the transaction	Direct Interest	Deemed Interest	Total
	Direct interest		10141
No. of voting shares/units held and/or underlying the rights/options/warrants/ convertible debentures :	0	331,120,528	331,120,528

<i>interest arises]</i> Jinhushen Biological Medical Science and Technology Co., Ltd. (the "Purchaser") acquired a 67% stake in Tianjin Pharmaceutical Holdings Co., Ltd. ("TPH") on 26 March 2021. As of the date of this notification, TPH directly holds 325,855,528 ordinary shares ("Shares") in the capital of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the "Company") which are listed on the Shanghai Stock Exchange. Pursuant to Section 4 of the Securities and Futures Act (Chapter 289 of Singapore ("SFA"), TPH is deemed interested in 5,265,000 Shares which are listed on the Official List of the Singapore Exchange Securities Trading Limited held by its wholly-owned subsidiary, Tianjin Pharmaceutical (Singapor International Investment Pte. Ltd	You may attach a chart in item 10 to illustrate how the Substantial Shareholder/Unitholder's deemed interest arises] Ilinhushen Biological Medical Science and Technology Co., Ltd. (the "Purchaser") acquired a 67% stake in Tianjin Pharmaceutical Holdings Co., Ltd. ("TPH") on 26 March 2021. As of the date of this notification. TPH directly holds 325.855.528 ordinary shares ("Shares") in the expital of Tianjin Pharmaceutical Roug Corporation Limited (the "Company") which are listed on the Shanghai Stock Exchange. Pursuant to Section 4 of the Securities and Futures Act (Chapter 280 of Singapore, ("SFA"), TPH is deemed interested in \$265,000 Shares which are listed on the Official List of the Singapore International investment Pte. Ltd. As the Purchaser holds a 67% stake in TPH as of the date of this notification, pursuant to Section 4 of the SFA. B. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: <i>IYou may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders</i>] Shanghai Ludiguang Medical Development Co., Ltd (Substantial Shareholder B) holds 35% of the shares in the capital of in earlier on the of the first notification which was announced on SGXNet (the <i>Thibial Announcement</i>): (a) SGXNet announcement reference of the first notification which was announced on SGXNet (the <i>Thibial Announcement</i>): (b) Date of the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: (c) 15-digit transaction reference of the first notification which was attached in the Initial Announcement: (c) 12-digit			
Tanjin Pharmacoulical Holdings Co., Ltd. ("TPH") on 26 March 2021. As of the date of this notification, TPH directly holds 325,855,258 ordinary shares ("Shares") in the capital of Tianjin Zhong Xin Pharmacoulical Group Corporation Limited (the "Company") which are listed on the Shanghai Stock Exchange. Pursuant to Section 4 of the Securities and Futures Act (Chapter 289 of Singapore ("SFA"). TPH is deemed interested in 5,265,000 Shares which are listed on the Official List of the Singapore Exchange Securities Trading Limited hold by its wholly-owned subsidiary. Tianjin Pharmacoutical (Singapor International Investment Pte. Ltd. As the Purchaser holds a 67% stake in TPH as of the date of this notification, pursuant to Section 4 of the SF. The Purchaser holds a 67% stake in TPH as of the date of this notification, pursuant to Section 4 of the SF. The Purchaser is deemed interested in the 331,120,528 Shares that TPH has an interest in pursuant to Section 4 of the SF. Prove may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders giving notice in this form: <i>I/You may</i> attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders] Sharaghai Luiliguang Medical Development Co., Ltd (Substantial Shareholder B) holds 35% of the shares in the capital of the Purchaser respectively. (a) Attachments (<i>if any</i>): (a) (the total file size for all attachment(s) should not exceed 1MB.) 11. If this is a replacement of an earlier notification, please provide: (a) SGXNet announcement reference of the first notification which was announced on SGXNet (the "Initial Announcement"): (b) Date of the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial	 Tianjin Pharmaceutical Holdings Co., Ltd. ("TPH") on 26 March 2021. As of the date of this notification, TPH directly holds 325,855,528 ordinary shares.") In the capital of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the "Company") which are listed on the Shanghal Slock Exchange. Pursuant to Section 4 of the Securities and Futures Att (Chapter 239 of Singapore (CSFA"), TPH is deemed interested in 5,26,000 Shares which are listed on the Official List of the Singapore Exchange Securities Trading Limited held by its wholly-owned subsidiary. Tianjin Pharmaceutical (Singapore International Investment Pfe. Ltd. As the Purchaser holds a 67% stake in TPH as of the date of this notification, pursuant to Section 4 of the SFA. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: <i>Prou may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders</i>] Bhanghai Luliguang Medical Development Co., Ltd (Substantial Shareholder B) holds 35% of the shares in the capital of the Purchaser respectively. (If this is a replacement of an earlier notification, please provide: (a) SGXNet announcement reference of the first notification which was announced on SGXNet (<i>the "Initial Announcement?</i>); (b) Date of the Initial Announcement?; (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement; (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement; 12. Remarks (<i>if any</i>): ① (a) Substantial Shareholder/Unitholder B) ① 	8.	[You	may attach a chart in item 10 to illustrate how the Substantial Shareholder/Unitholder's deemed
As of the date of this notification. TPH directly holds 325,855,528 ordinary shares ("Shares") in the capital of Tlanjin Zhong Xin Pharmaceutical Group Corporation Limited (the "Company") which are listed on the Bhanghai Stock Exchange. Pursuant to Section 4 of the Securities and Futures Act (Chapter 229 of Singapore Exchange Securities Trading Limited held by its wholly-owned subsidiary. Tianjin Pharmaceutical (Singapore International Investment Pte. Ltd. As the Purchaser holds a 67% stake in TPH as of the date of this notification, pursuant to Section 4 of the SF. 9. Relationship between the Substantial Shareholders/Unitholders glying notice in this form: <i>Nou may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]</i> 9. Relationship between the Substantial Shareholders/Unitholders glying notice in this form: <i>Nou may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]</i> 9. Relationship between the Substantial Shareholders/Unitholders glying notice in this form: <i>Nou may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]</i> 9. Relationship between the Substantial Shareholders/Unitholders glying notice in this form: <i>Nou may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]</i> 9. Relationship between the Substantial Shareholders/Unitholders glying the capital of the Purchaser respectively. 10. Attachments (<i>if any</i>): ③ 11. If this is a replacement of an earlier notification, please provide: (a) SGXNet announcement reference of the <u>first</u> notification which was announced on SGXNet (<i>the "</i>	As of the date of this notification. TPH directly holds 325.855.528 ordinary shares ("Shares") in the capital of Tranjin Zhong Xin Pharmaceutical Group Corporation Limited (the "Company") which are listed on the Bhanghai Stock Exchange. Pursuani to Section 4 of the Securities and Futures Act (Chapter 289 of Singapore) ("SFA"). THis is deemed interested in 526,000 Shares which are listed on the Official List of the Singapore Exchange Securities Trading Limited held by its wholly-owned subsidiary. Tianjin Pharmaceutical (Singapore International Investment Pte. Ltd. As the Purchaser holds a 57% stake in TPH as of the date of this notification, pursuant to Section 4 of the SFA. 9. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: IYou may attech a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders] 9. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: IYou may attech a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders] 9. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: IYou may attech a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders] 9. Relationship between the form 10 to show the relationship between the Substantial Shareholders/Unitholders] 9. Relationship between the Substantial Shareholders/Unitholders by holds 35% of the shares in the capital of the Purchaser respectively. 10. Attachments (if any): Image: Source of the first notification which was announced on SGXNet (the "Initial Announcement"): Image: Source of the Initial Announcement: Im			
the Purchaser is deemed interested in the 331,120,528 Shares that TPH has an interest in pursuant to Section 4 of the SFA. 9. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: //our may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders] Shanghai Lluliguang Medical Development Co., Ltd (Substantial Shareholder B) holds 35% of the shares in the capital of the Purchaser respectively. 10. Attachments (if any): Image: Comparison of the size for all attachment(s) should not exceed 1MB.) 11. If this is a replacement of an earlier notification, please provide: (a) SGXNet announcement reference of the first notification which was announced on SGXNet (the "Initial Announcement"): Image: Comparison of the lottial Announcement: Image: Comparison of the lottial Announcement: <t< td=""><td>the Purchaser is deemed interested in the 331,120,528 Shares that TPH has an interest in pursuant to Section 4 of the SFA. 9. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: <i>Nou may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]</i> Shanghai Lluliguang Medical Development Co., Ltd (Substantial Shareholder B) holds 35% of the shares in the capital of the Purchaser respectively. 10. Attachments (<i>if any</i>): If this is a replacement of an earlier notification, please provide: (a) SGXNet announcement reference of the first notification which was announced on SGXNet (<i>the "Initial Announcement"</i>): Image: the lnitial Announcement: Image: the lnitial Announcement: Image: the lnitial Shareholder/Unitholder B (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: Image: the lnitial Shareholder/Unitholder B Substantial Shareholder/Unitholder B 10. Name of Substantial Shareholder/Unitholder:</td><td></td><td>As of Tianji Shanç ("SFA" Excha</td><td>the date of this notification, TPH directly holds 325,855,528 ordinary shares ("Shares") in the capital of n Zhong Xin Pharmaceutical Group Corporation Limited (the "Company") which are listed on the ghai Stock Exchange. Pursuant to Section 4 of the Securities and Futures Act (Chapter 289 of Singapore) '), TPH is deemed interested in 5,265,000 Shares which are listed on the Official List of the Singapore inge Securities Trading Limited held by its wholly-owned subsidiary, Tianjin Pharmaceutical (Singapore</td></t<>	the Purchaser is deemed interested in the 331,120,528 Shares that TPH has an interest in pursuant to Section 4 of the SFA. 9. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: <i>Nou may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]</i> Shanghai Lluliguang Medical Development Co., Ltd (Substantial Shareholder B) holds 35% of the shares in the capital of the Purchaser respectively. 10. Attachments (<i>if any</i>): If this is a replacement of an earlier notification, please provide: (a) SGXNet announcement reference of the first notification which was announced on SGXNet (<i>the "Initial Announcement"</i>): Image: the lnitial Announcement: Image: the lnitial Announcement: Image: the lnitial Shareholder/Unitholder B (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: Image: the lnitial Shareholder/Unitholder B Substantial Shareholder/Unitholder B 10. Name of Substantial Shareholder/Unitholder:		As of Tianji Shanç ("SFA" Excha	the date of this notification, TPH directly holds 325,855,528 ordinary shares ("Shares") in the capital of n Zhong Xin Pharmaceutical Group Corporation Limited (the "Company") which are listed on the ghai Stock Exchange. Pursuant to Section 4 of the Securities and Futures Act (Chapter 289 of Singapore) '), TPH is deemed interested in 5,265,000 Shares which are listed on the Official List of the Singapore inge Securities Trading Limited held by its wholly-owned subsidiary, Tianjin Pharmaceutical (Singapore
You may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders] Shanghai Liuliguang Medical Development Co., Ltd (Substantial Shareholder B) holds 35% of the shares in the capital of the Purchaser respectively. 10. Attachments (if any): (i) Image: Constraint of the Purchaser respectively. Image: Constraint of the Purchaser respectively. </td <td>You may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders] Shanghai Liuliguang Medical Development Co., Ltd (Substantial Shareholder B) holds 35% of the shares in the capital of the Purchaser respectively. 10. Attachments (<i>if any</i>): ③</td> <td></td> <td>the Pu</td> <td>urchaser is deemed interested in the 331,120,528 Shares that TPH has an interest in pursuant to Section</td>	You may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders] Shanghai Liuliguang Medical Development Co., Ltd (Substantial Shareholder B) holds 35% of the shares in the capital of the Purchaser respectively. 10. Attachments (<i>if any</i>): ③		the Pu	urchaser is deemed interested in the 331,120,528 Shares that TPH has an interest in pursuant to Section
the capital of the Purchaser respectively. 10. Attachments (if any): () () <tr< td=""><td>the capital of the Purchaser respectively. 10. Attachments (<i>if any</i>): ① If this is a replacement of an earlier notification, please provide: (a) SGXNet announcement reference of the first notification which was announced on SGXNet (<i>the "Initial Announcement"</i>): (b) Date of the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 4 (c) 15-digit transaction reference number of the relevant transaction in the Form 5 (c) 15-digit transaction reference</td><td>9.</td><td>[You</td><td>may attach a chart in item 10 to show the relationship between the Substantial</td></tr<>	the capital of the Purchaser respectively. 10. Attachments (<i>if any</i>): ① If this is a replacement of an earlier notification, please provide: (a) SGXNet announcement reference of the first notification which was announced on SGXNet (<i>the "Initial Announcement"</i>): (b) Date of the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 3 (c) 15-digit transaction reference number of the relevant transaction in the Form 4 (c) 15-digit transaction reference number of the relevant transaction in the Form 5 (c) 15-digit transaction reference	9.	[You	may attach a chart in item 10 to show the relationship between the Substantial
(The total file size for all attachment(s) should not exceed 1MB.) 11. If this is a replacement of an earlier notification, please provide: (a) SGXNet announcement reference of the first notification which was announced on SGXNet (<i>the "Initial Announcement"</i>): (b) Date of the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: 12. Remarks (<i>if any</i>): Substantial Shareholder/Unitholder B (1. Name of Substantial Shareholder/Unitholder:	(The total file size for all attachment(s) should not exceed 1MB.) 11. If this is a replacement of an earlier notification, please provide: (a) SGXNet announcement reference of the first notification which was announced on SGXNet (<i>the "Initial Announcement"</i>): (b) Date of the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: 12. Remarks (<i>if any</i>): Substantial Shareholder/Unitholder B (a) Name of Substantial Shareholder/Unitholder:			
(The total file size for all attachment(s) should not exceed 1MB.) 11. If this is a replacement of an earlier notification, please provide: (a) SGXNet announcement reference of the first notification which was announced on SGXNet (<i>the "Initial Announcement"</i>): (b) Date of the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: 12. Remarks (<i>if any</i>): Substantial Shareholder/Unitholder B (1. Name of Substantial Shareholder/Unitholder:	(The total file size for all attachment(s) should not exceed 1MB.) 11. If this is a replacement of an earlier notification, please provide: (a) SGXNet announcement reference of the first notification which was announced on SGXNet (<i>the "Initial Announcement"</i>): (b) Date of the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: 12. Remarks (<i>if any</i>): Substantial Shareholder/Unitholder B (a) Name of Substantial Shareholder/Unitholder:			
11. If this is a replacement of an earlier notification, please provide: (a) SGXNet announcement reference of the first notification which was announced on SGXNet (the "Initial Announcement"): (b) Date of the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: 12. Remarks (if any): Substantial Shareholder/Unitholder p (1. Name of Substantial Shareholder/Unitholder:	11. If this is a replacement of an earlier notification, please provide: (a) SGXNet announcement reference of the <u>first</u> notification which was announced on SGXNet (<i>the "Initial Announcement"</i>): (b) Date of the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: 12. Remarks (<i>if any</i>): Substantial Shareholder/Unitholder B (1. Name of Substantial Shareholder/Unitholder:	10.	Atta	chments (<i>if any</i>):
 (a) SGXNet announcement reference of the <u>first</u> notification which was announced on SGXNet (<i>the "Initial Announcement"</i>): (b) Date of the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: 12. Remarks (<i>if any</i>): 	 (a) SGXNet announcement reference of the <u>first</u> notification which was announced on SGXNet (<i>the "Initial Announcement"</i>): (b) Date of the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: 12. Remarks (<i>if any</i>): 		Ø	(The total file size for all attachment(s) should not exceed 1MB.)
on SGXNet (the "Initial Announcement"): (b) Date of the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: 12. Remarks (if any): Substantial Shareholder/Unitholder B 1. Name of Substantial Shareholder/Unitholder:	on SGXNet (the "Initial Announcement"): (b) Date of the Initial Announcement: (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: 12. Remarks (<i>if any</i>): Substantial Shareholder/Unitholder B (1. Name of Substantial Shareholder/Unitholder:	11.	lf thi	s is a replacement of an earlier notification, please provide:
(c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: 12. Remarks (<i>if any</i>): Substantial Shareholder/Unitholder B 1. Name of Substantial Shareholder/Unitholder:	(c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: 12. Remarks (<i>if any</i>): Substantial Shareholder/Unitholder B 1. Name of Substantial Shareholder/Unitholder:		(a)	
(c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: 12. Remarks (<i>if any</i>): 12. Substantial Shareholder/Unitholder B 14. Name of Substantial Shareholder/Unitholder:	(c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement: 12. Remarks (<i>if any</i>): 12. Substantial Shareholder/Unitholder B 14. Name of Substantial Shareholder/Unitholder:			
which was attached in the Initial Announcement: 12. Remarks (<i>if any</i>): Substantial Shareholder/Unitholder B 1. Name of Substantial Shareholder/Unitholder:	which was attached in the Initial Announcement: 12. Remarks (<i>if any</i>): Substantial Shareholder/Unitholder B 1. Name of Substantial Shareholder/Unitholder:		(b)	Date of the Initial Announcement:
which was attached in the Initial Announcement: 12. Remarks (<i>if any</i>): Substantial Shareholder/Unitholder B 1. Name of Substantial Shareholder/Unitholder:	which was attached in the Initial Announcement: 12. Remarks (<i>if any</i>): Substantial Shareholder/Unitholder B 1. Name of Substantial Shareholder/Unitholder:			
12. Remarks (<i>if any</i>): Substantial Shareholder/Unitholder B (1) Name of Substantial Shareholder/Unitholder:	12. Remarks (<i>if any</i>): Substantial Shareholder/Unitholder B 1. Name of Substantial Shareholder/Unitholder:		(c)	5
Substantial Shareholder/Unitholder B 1. Name of Substantial Shareholder/Unitholder:	Substantial Shareholder/Unitholder B 1.			
Substantial Shareholder/Unitholder B Image: Constantial Shareholder/Unitholder: 1. Name of Substantial Shareholder/Unitholder:	Substantial Shareholder/Unitholder B Image: The second	12.	Rem	harks (<i>if any</i>):
1. Name of Substantial Shareholder/Unitholder:	1. Name of Substantial Shareholder/Unitholder:			
1. Name of Substantial Shareholder/Unitholder:	1. Name of Substantial Shareholder/Unitholder:			
1. Name of Substantial Shareholder/Unitholder:	1. Name of Substantial Shareholder/Unitholder:			
1. Name of Substantial Shareholder/Unitholder:	1. Name of Substantial Shareholder/Unitholder:			
		<u>Sub</u>	stantia	al Shareholder/Unitholder B
Shanghai Liuliguang Medical Development Co., Ltd ("SLMDC")	Shanghai Liuliguang Medical Development Co., Ltd ("SLMDC")	1.	Nam	ne of Substantial Shareholder/Unitholder:
			Shan	ghai Liuliguang Medical Development Co., Ltd ("SLMDC")

- 2. Is Substantial Shareholder/Unitholder a fund manager or a person whose interest in the securities of the Listed Issuer are held solely through fund manager(s)?
 - Yes
 - ✓ No
- 3. Notification in respect of:
 - ✓ Becoming a Substantial Shareholder/Unitholder
 - Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder
 - Ceasing to be a Substantial Shareholder/Unitholder
- 4. Date of acquisition of or change in interest:

26-Mar-2021

5. Date on which Substantial Shareholder/Unitholder became aware of the acquisition of, or the change in, interest (if different from item 4 above, please specify the date):

26-Mar-2021	

- 6. Explanation (*if the date of becoming aware is different from the date of acquisition of, or the change in, interest*):
- 7. Quantum of total voting shares/units (*including voting shares/units underlying rights/options/warrants/convertible debentures {conversion price known}*) held by Substantial Shareholder/Unitholder before and after the transaction:

Immediately before the transaction	Direct Interest	Deemed Interest	Total
No. of voting shares/units held and/or underlying the rights/options/warrants/convertible debentures:	0	0	0
As a percentage of total no. of voting shares/(0	0	0
Immediately after the transaction	Direct Interest	Deemed Interest	Total
No. of voting shares/units held and/or underlying the rights/options/warrants/ convertible debentures :	0	331,120,528	331,120,528
As a percentage of total no. of voting shares/(0	42.8	42.8

8. Circumstances giving rise to deemed interests (*if the interest is such*): [You may attach a chart in item 10 to illustrate how the Substantial Shareholder/Unitholder's deemed interest arises]

	Please refer to Paragraph 8 of Substantial Shareholder A's notification.								
	Pursuant to Section 4 of the SFA, as SLMDC has a 35% equity interest in the Purchaser, SLMDC is deemed to have an interest in Shares in which the Purchaser is deemed to have an interest.								
9.	Relationship between the Substantial Shareholders/Unitholders giving notice in this form: [You may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]								
	SIIC S	hanghai (Holdings) Co., Ltd. (Substantial Shareholder C) owns 51% of the equity interests in SLMDC.							
10.	Atta	chments (<i>if any</i>): 👔							
	Ø	(The total file size for all attachment(s) should not exceed 1MB.)							
11.	lf thi	s is a replacement of an earlier notification, please provide:							
	(a)	SGXNet announcement reference of the <u>first</u> notification which was announced on SGXNet (<i>the "Initial Announcement"</i>):							
	(b)	Date of the Initial Announcement:							
	(c)								
	()	15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement:							
12.									
	Rem	which was attached in the Initial Announcement: arks (if any): al Shareholder/Unitholder ()							
	Rem stantia	which was attached in the Initial Announcement:							
Sub	Rem stantia	which was attached in the Initial Announcement: arks (if any): al Shareholder/Unitholder ()							
Sub	Rem stantia Nam SIIC S Is S secu	which was attached in the Initial Announcement:							
<u>Sub</u> 1. 2.	Rem stantia Nam SIIC S Is S secu Y V N	which was attached in the Initial Announcement:							
<u>Sub</u> 1.	Rem stantia Nam SIIC S Is S secu Y V N	which was attached in the Initial Announcement:							
<u>Sub</u> 1. 2.	Rem stantia Nam SIIC S Is S secu Y V N Notif	which was attached in the Initial Announcement:							

4. Date of acquisition of or change in interest:

26-Mar-2021

5. Date on which Substantial Shareholder/Unitholder became aware of the acquisition of, or the change in, interest (i) (if different from item 4 above, please specify the date):

26-Mar-2021

- 6. Explanation (*if the date of becoming aware is different from the date of acquisition of, or the change in, interest*):
- 7. Quantum of total voting shares/units (*including voting shares/units underlying rights/options/warrants/convertible debentures {conversion price known}*) held by Substantial Shareholder/Unitholder before and after the transaction:

Immediately before the transaction	Direct Interest	Deemed Interest	Total
No. of voting shares/units held and/or underlying the rights/options/warrants/convertible debentures:	0	0	0
As a percentage of total no. of voting shares/():	0	0	0
Immediately after the transaction	Direct Interest	Deemed Interest	Total
Immediately after the transaction No. of voting shares/units held and/or underlying the rights/options/warrants/ convertible debentures :	Direct Interest	Deemed Interest 331,120,528	Total 331,120,528

8. Circumstances giving rise to deemed interests (*if the interest is such*): [You may attach a chart in item 10 to illustrate how the Substantial Shareholder/Unitholder's deemed

interest arises]

Please refer to Paragraph 8 of Substantial Shareholder A's notification and Paragraph 8 of Substantial Shareholder B's notification.

Pursuant to Section 4 of the SFA, as SIIC has a 51% equity interest in SLMDC, SIIC is deemed to have an interest in Shares in which the Purchaser is deemed to have an interest.

9. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: [You may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]

The Shanghai State-owned Assets Supervision and Administration Commission (Substantial Shareholder D) owns 100% of the equity interests in SIIC.

10.	. Attachments (<i>if any</i>):
	(The total file size for all attachment(s) should not exceed 1MB.)
11.	If this is a replacement of an earlier notification, please provide:
	(a) SGXNet announcement reference of the <u>first</u> notification which was announced on SGXNet (<i>the "Initial Announcement"</i>):
	(b) Date of the Initial Announcement:
	(c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement:
12.	. Remarks (<i>if any</i>):
Suk	bstantial Shareholder/Unitholder D
1.	Name of Substantial Shareholder/Unitholder: Shanghai State-owned Assets Supervision and Administration Commission
•	
2.	Is Substantial Shareholder/Unitholder a fund manager or a person whose interest in the securities of the Listed Issuer are held solely through fund manager(s)?
3.	Notification in respect of:
0.	Becoming a Substantial Shareholder/Unitholder
	Change in the percentage level of interest while still remaining a Substantial Shareholder/Unithol
	Ceasing to be a Substantial Shareholder/Unitholder
4.	Date of acquisition of or change in interest:
	26-Mar-2021
5.	Date on which Substantial Shareholder/Unitholder became aware of the acquisition of, or th change in, interest () (if different from item 4 above, please specify the date):
	26-Mar-2021
6.	Explanation (if the date of becoming aware is different from the date of acquisition of, or th change in, interest):

7. Quantum of total voting shares/units (*including voting shares/units underlying rights/options/warrants/convertible debentures {conversion price known}*) held by Substantial Shareholder/Unitholder before and after the transaction:

Immediately before the transaction	Direct Interest	Deemed Interest	Total
No. of voting shares/units held and/or underlying the rights/options/warrants/convertible debentures:	0	0	0
As a percentage of total no. of voting shares/د):	0	0	0
Immodiately after the transaction			—
Immediately after the transaction	Direct Interest	Deemed Interest	Total
No. of voting shares/units held and/or underlying the rights/options/warrants/ convertible debentures :	0	331,120,528	331,120,528

8. Circumstances giving rise to deemed interests (*if the interest is such*): [You may attach a chart in item 10 to illustrate how the Substantial Shareholder/Unitholder's deemed interest arises]

Please refer to Paragraph 8 of Substantial Shareholder A's notification, Paragraph 8 of Substantial Shareholder B's notification and Paragraph 8 of Substantial Shareholder C's notification.

Pursuant to Section 4 of the SFA, as Shanghai State-owned Assets Supervision and Administration Commission ("Shanghai SASAC") holds 100% of the equity interests in SIIC, Shanghai SASAC is deemed to have an interest in Shares in which the Purchaser is deemed to have an interest.

9. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: [You may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]

10. Attachments (if any): 🕤

(The total file size for all attachment(s) should not exceed 1MB.)

- 11. If this is a **replacement** of an earlier notification, please provide:
 - (a) SGXNet announcement reference of the <u>first</u> notification which was announced on SGXNet (*the "Initial Announcement"*):
 - (b) Date of the Initial Announcement:
 - (c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement:

12. Remarks (if any):

Part IV - Transaction details

	osen): Voting shares/units
	Rights/Options/Warrants over voting shares/units
	Convertible debentures over voting shares/units (conversion price known)
✓	Others (<i>please specify</i>):
Ple	ase refer to item 4 below.
	mber of shares, units, rights, options, warrants and/or principal amount of convertib pentures acquired or disposed of by Substantial Shareholders/Unitholders:
N.A	A. Please refer to item 4 below.
	nount of consideration paid or received by Substantial Shareholders/Unitholders (<i>excluding</i> bkerage and stamp duties):
N.A	A. Please refer to item 4 below.
Cir	cumstance giving rise to the interest or change in interest:
Aco	quisition of:
	Securities via market transaction
	Securities via off-market transaction (e.g. married deals)
	Securities via physical settlement of derivatives or other securities
	Securities pursuant to rights issue
	Securities via a placement
	Securities following conversion/exercise of rights, options, warrants or other convertibles
Dis	posal of:
	Securities via market transaction
	Securities via off-market transaction (e.g. married deals)
Oth	ner circumstances:
	Acceptance of take-over offer for the Listed Issuer
	Corporate action by the Listed Issuer which Substantial Shareholders/Unitholders did not participate in (<i>please specify</i>):
	Others (<i>please specify</i>):

Item 5 is to be completed by an individual submitting this notification form on behalf of the Substantial Shareholders/Unitholders.

- 5. Particulars of Individual submitting this notification form to the Listed Issuer:
 - (a) Name of Individual:

Jinzhu Chen

(b) Designation (*if applicable*):

General Manager

(c) Name of entity (*if applicable*): Jinhushen Biological Medical Science and Technology Co., Ltd.

Transaction Reference Number (auto-generated):

		2	1	5	4	3	0	4	4	2	8	2	3	9	8	3
--	--	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---